Docket No.: GNE.3230R1C52



INFORMATION DISCLOSURE STATEMENT

pplicant

Goddard, et al.

App. No

10/063,578

Filed

May 3, 2002

For

SECRETED

AND

TRA

TRANSMEMBRANE POLYPEPTIDES

AND NUCLEIC ACIDS ENCODING

THE SAME

Examiner

Rachel Kapust Hunnicutt

Art Unit

1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

March 11, 2005 (Date)

metanix to

er, Reg. No. 37,649

nneMarie Kais

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is an Information Disclosure Statement by Applicant (PTO/SB/08 equivalent) listing 26 references to be considered by the Examiner. Also enclosed are 13 non-patent references as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed after the mailing date of a final action or after the mailing date of a Notice of Allowance. This Statement is accompanied by the fee set forth in 37 C.F.R. § 1.17(p). The Commissioner is hereby authorized to charge any additional fees which may be required or to credit any overpayment to Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

03/15/2005 EABUBAK1 00000073 10063578

01 FC:1806

180.00 OP

AnneMarie Kaiser

Registration No. 37,649

Attorney of Record

Customer No. 30313

(619) 235-8550

1334237_1\031105

INFORMATION DISCLOSURE
OTP STATEMENT BY APPLICANT

(Language of the control of the cont

SHEET 1 OF 2

MAR 1 4 2005

Application No.	10/063,578
Filing Date	May 3, 2002
First Named Inventor	Goddard, et al.
Art Unit	1647
Examiner	HUNNICUTT, RACHEL KAPUST
Attorney Docket No.	GNE.3230R1C52

at at	\$/		U.S. PATENT	DOCUMENTS	
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	1	US6025156	02-15-2000	Gwynn, et al.	
	2	US6124433	09-26-2000	Falb, et al.	
	3	US6156500	12-05-2000	Falb, Dean	
	4	US6162604	12-19-2000	Jacob, Chaim O.	
	5	US6228582	05-08-2001	Rodier, et al.	
	6	US6395306	05-28-2002	Cui, et al.	
	7	US6414117	07-02-2002	Levinson, Douglas Adam	
	8	US6465185	10-15-2002	Goldfine, et al.	
	9	US6498235	12-24-2002	Sheppard, et al.	
	10	US6562343	05-13-2003	Levinson, Douglas Adam	
	11	US6645499	11-11-2003	Lal, et al.	
	12	US6730502	05-04-2004	Va, et al.	
	13	US6737522	05-18-2004	Sundick, et al.	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ¹
	14	ALBERTS et al. 1994. <i>Molecular Biology of the Çell 3rd Edition</i> , Garland Publishing NY, (ISBN: 0-8153-1619-4).	
	15	ALBERTS et al. 2002. <i>Molecular Biology of the Cell 4th Edition</i> , Garland Publishing NY, (ISBN: 0-8153-3218-1).	
	16	GRIMALDI, et al. 1989. The t(5;14) Chromosomal Translocation in a Case of Acute Lymphotic Leukemia Joins the Interleukin-3 Gene to the Immunoglobulin Heavy Chain Gene. <i>Blood</i> , 73(8):2081-2085.	
	17	HANNA, et al. August 1999. HER-2/neu Breast Cancer Predictive Testing. <i>Pathology Associates Medical Laboratories</i> .	
	18	HYMAN et al. Nov. 2002. Impact of DNA Amplification of Gene Expression Patterns. Cancer Research, 62:6240-6245.	
	19	LEWIN, 1994. Oncogenes: Gene Expression and Cancer. Genes V, Ch. 39:1196-1201.	
	20	LEWIN, 1997. Regulation of Transcription. Genes VI. Ch. 29:847-848.	_

Examiner Signature	
--------------------	--

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T¹ - Place a check mark in this area when an English language Translation is attached.

	Application No.	10/063,578
INFORMATION DISCLOSURE	Filing Date	May 3, 2002
	First Named Inventor	Goddard, et al.
STATEMENT BY APPLICANT	Art Unit	1647
Multiple sheets used when necessary)	Examiner	HUNNICUTT, RACHEL KAPUST
SHEET 2 OF 2	Attorney Docket No.	GNE.3230R1C52

PADEMARK	/	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T¹
	21	MEEKER, et al. July 15, 1990. Activation of the Interleukin-3 Gene by Chromosome Translocation in Acute Lymphotic Leukemia with Eosinophilia. <i>Blood</i> , 76(2):285-289.	
MERIC et al. 2002. Translation		MERIC et al. 2002. Translation Initiation in Cancer: A Novel Target For Therapy. <i>Molecular Cancer Therapeutics</i> , 1:971-979.	
	23	ORNTOFT et al. 2001. Genome-wide Study of Gene Copy Numbers -Transcripts, and Protein Levels in Pairs of Non-invasive and Invasive Human Transitional Cell Carcinomas. <i>Molecular and Cellular Proteomics</i> 1.1:39.	
	24	POLLACK et al. Oct 2002. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of breast tumors. <i>PNAS</i> 99(20).	
	25	SINGLETON, et al. 1992. Clinical and Pathologic Significance of the c-erbB-2 (HER-2/neu) Oncogene. <i>Pathol. Annu</i> , 1(27):165-190.	
	26	ZHIGANG et al. 2004. Prostate stem cell antigen (PSCA) expression in human prostate cancer tissues and its potential role in prostate carcinogenesis and progression of prostate cancer. World Journal of Surgical Oncology, 2:13.	

1334131_1 031105

Examiner Signature

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.